Kornimate/medical-research-clean huggingface dataset:
the effect of huperzine a injection on postoperative cognitive dysfunction in patients with aneurysmal subarachnoid hemorrhage: a pilot study

Conditions: Postoperative Cognitive Dysfunction in Patients With Aneurysmal Subarachnoid Hemorrhage

Summary: under the premise of basic treatment, to explore the improvement effect of huperzine a injection on short-term and long-term neurocognitive dysfunction in patients with aneurysmal subarachnoid hemorrhage after interventional/surgical treatment.

description: this is a randomized, controlled, single center, exploratory clinical trial. the subjects are divided into surgical treatment group and interventional treatment group. each group is divided into test group and control group. the test group is given huperzine a injection (0.2mg/dose) every day, intramuscular injection, for a total of 8 days, and basic treatment is given at the same time; the control group was given basic treatment, and did not receive other neurotrophic drugs except basic drugs. this clinical trial is to evaluate the effect of huperzine a injection on the improvement of postoperative cognitive dysfunction in patients with aneurysmal subarachnoid hemorrhage.

Eligibility criteria:
inclusion criteria: * age 18-70; * the patients were proved to be aneurysmal subarachnoid hemorrhage by imaging examination (head ct, ct angiography (cta), whole brain angiography (dsa)); * hunt hess was graded i-iii at admission; * the patients were treated with endovascular therapy or craniotomy and clipping surgery; * the time from the onset of asah symptoms to admission ≤ 72 hours; ⑥ the subject himself or the guardian of the subject knew and voluntarily signed the informed consent form. exclusion criteria: * non aneurysmal subarachnoid hemorrhage; * cognitive dysfunction existed before onset; * patients with angina pectoris, bronchial asthma, mechanical intestinal obstruction, liver and kidney insufficiency, and urinary tract obstruction; * complicated with other nervous system diseases, including nervous system degenerative diseases (alzheimer's disease, parkinson's disease, lewy body dementia, frontotemporal dementia, etc.), neuromyelitis optica, epilepsy, central nervous system infection (such as aids, syphilis, etc.), brain traumatic dementia, etc; * psychotic patients, according to dsm-iv-tr standards, including schizophrenia or other mental diseases, bipolar disorder, major depression or delirium; * other cholinesterase inhibitor drugs are being used; ⑦ there are uncorrectable visual and auditory disorders, and neuropsychological tests and scales cannot be completed; * have unstable or serious heart, lung, liver, kidney and hematopoietic system diseases; * pregnant or lactating women and women of childbearing age without reliable contraception, and there is no evidence of negative pregnancy; ⑩ patients who cannot be followed up as required during the study period; ⑪ those who are allergic to the test drug; ⑫ those who have participated in other clinical trials in recent 3 months; ⑬ patients who are not suitable to participate in the clinical trial.
effects of tranexamic acid on blood loss and transfusion requirement following hip fracture

Conditions: Hip Fracture

Summary: tranexamic acid (ta) inhibits fibrinolysis by binding to lysine binding-sites of plasminogen to fibrin. fibrinolysis is stimulated by surgical trauma, and the administration of ta has been shown effective in decreasing blood loss both intra-operatively and in the immediate post-operative period in elective hip and knee arthroplasty patients. both the timing and dosing of ta has been investigated in these patients. subsequent blood transfusion rate has also been shown to decrease as result of ta administration. despite the support for ta utilization that exists in the arthroplasty literature, the data is scarce regarding its administration during surgical treatment of hip fractures. this is patient population who is at high risk for transfusion due to symptomatic post-operative anemia. this study aims to investigate whether ta's advantageous effects in the arthroplasty patient population can be extrapolated to the more unstable, heterogeneous hip fracture patient population. if the study is able to show a difference in blood loss and transfusion requirement, the long term implications of this with regards to cost and mortality can be significant.


Eligibility criteria:
inclusion criteria: patients admitted to bryn mawr hospital with fracture of the femoral neck, intertrochanteric region, or subtrochanteric region of the femur will be considered for the study. exclusion criteria: exclusion criteria include * age under 18 * allergy to ta * known current or history of venous thromboembolism (vte) * history of known coagulopathy or bleeding disorder * current subarachnoid hemorrhage * previous history of seizures * current use of estrogen/progesterone therapy * renal failure defined as creatinine clearance less than 30 ml/min4 * multiple fractures * pregnant or breastfeeding women * planned nonoperative management of the fracture
a study of the efficacy and safety of carbidopa-levodopa extended-release tablets in patients with parkinson's disease

Conditions: Parkinson Disease

Summary: it is a phase ii randomized, parallel, double-blind, placebo-controlled, multi-center clinical trial of the efficacy and safety of wd-1603 carbidopa-levodopa extended-release tablets in patients with parkinson's disease. the objective of the study is to access the safety and efficacy of wd-1603 carbidopa-levodopa extended-release tablets in patients with parkinson's disease.

eligible subjects of the study will be randomly assigned into four groups at a ratio of 1:1:1:1: three treatment groups and one placebo group. the subjects will take trial drugs orally three times a day, in the morning before meals, and the second and third medications will be taken after meals, once every 5 hours.

Eligibility criteria:
inclusion criteria: 1. male/female patients with early parkinson's disease who are over 30 years old and under 75 years old (including cut-off values). 2. able to understand and willing to sign an informed consent form (icf) voluntarily. 3. the diagnosis of parkinson's disease complies with idiopathic parkinson's disease (2015 version of mds parkinson's disease diagnostic criteria). 4. modified hoehn and yahr scale≥1, ≤2.5 points. 5. agree to use medically acceptable contraceptive methods throughout the study and within 1 month after completing the study. exclusion criteria: 1. have a history of severe allergic reactions or allergies to levodopa or carbidopa. 2. pregnancy or breastfeeding. 3. diagnosed as atypical parkinson's disease or any known secondary parkinson's syndrome. 4. the investigator believes that the placebo treatment cannot be tolerated. 5. acute psychosis or hallucinations, using any antipsychotic to treat psychosis or clinically obvious depression. 6. history of epilepsy or epilepsy. 7. the history of narrow-angle glaucoma. 8. subjects with a history of malignant melanoma. 9. patients with obvious cognitive impairment. 10. the investigator believes that there are clinically significant medical or surgical diseases and patients who are not suitable for participating in clinical trials.

Keywords: wd-1603 carbidopa-levodopa extended-release tablets
apraxia in parkinson's disease patients with deep brain stimulation

Conditions: Deep Brain Stimulation; Parkinson Disease; Apraxia, Motor

Summary: deep brain stimulation (dbs) of the subthalamic nucleus or globus pallidus internus can improve motor symptoms parkinson's disease (pd). however, it is not known whether dbs can help reduce the signs and symptoms of the limb-kinetic, ideomotor or ideational apraxia associated with pd or if apraxia can exist as a stimulation induced side effect from dbs therapy. in this study, we look to conduct a pilot study to examine the feasibility of characterizing the prevalence of apraxia in pd patients with chronic, stable dbs.

this will be a pilot study designed to assess the safety and feasibility of an apraxia testing protocol in chronically implanted pd dbs patients. we hypothesize that apraxia testing in the dbs on and off states will be a safe and well-tolerated testing protocol. we also hypothesize that dbs will affect the severity of limb-kinetic, ideomotor and ideational apraxia in pd patients. this will set the foundation for larger prospective trials to further characterize apraxia in relation to dbs and whether or not dbs programming can modulate this phenomenon. in this study, we will recruit 60 pd patients with chronic, stable dbs of either the subthalamic nucleus (stn) or globus pallidus interna (gpi). both unilateral and bilateral dbs patients are eligible for this study. for this study, "chronic, stable dbs" will be defined as patients who have had at least 6 months of optimization programming at the university of florida. the subjects will be recruited to the fixel clinic for a 1-day study visit in the medication on state. the patients will undergo testing for limb-kinetic, ideomotor and ideational apraxia of both upper extremities in the dbs on state at home therapeutic settings.

Eligibility criteria:
inclusion criteria: 1. patients with pd as defined by the uk brain bank criteria 2. male or female, ages 18 to 80 years old 3. chronically implanted dbs of either the stn or gpi for a minimum of 6 months exclusion criteria: 1. other neurological diagnoses (e.g. alzheimer's disease, atypical parkinsonism, stroke) 2. history of previous neurosurgical intervention that was not dbs 3. patients with dbs of targets other than the stn or gpi, or leads in both targets 4. patients in whom there is poor manual dexterity for a reason other than pd (e.g. orthopedic injury, amputation) 5. patients with a diagnosis of pd dementia
assessment of facilitated tucking during the procedure of daily weight on the level of stress in preterm infants

Conditions: Stress

Summary: randomized crossover clinical trial in which is intended to assess the effect of facilitated tucking of premature infants during daily weight. heart rate, respiratory rate and neo-scale stress (alps-neo) be observed before, during and one hour after the weight, and compared with normal practice, without facilitated tucking device.

population(n): 20 newborn when a patient is a possible candidate, consent will be asked their parents. after obtaining informed consent signed by parents, it will be assigned a random group (g1, g2). in the g1, the first weight without facilitated tucking device and the next day with facilitated tucking device will be held. g2 will be done in reverse. handling pre phase (t0): at least 20 minutes before vitals heart rate and respiratory rate are taken in five times. handling phase (t1): 1. the facilitated tucking device is placed. 2. will wait five minutes and weight will be held in the incubator;at the time of leaving it in the incubator the same constants are taken. post handling phase (t2): the same constants are taken one hour after such manipulation.

Eligibility criteria:
inclusion criteria: * ≤1500 grams newborns * a week of life about exclusion criteria: * surgery * hemodynamic instability requiring vasoactive drugs * sedation * phototherapy at the time of the procedure * congenital anomalies.

Keywords: newborn facilitated tucking position weight stress
point-of-care echocardiography in patients with known or suspected aortic stenosis

Conditions: Patients with an Indication for an Echocardiographic Examination with Suspicion of Valcular Heart Disease

Summary: this is a prospective clinical trial intended to capture echocardiographic images in patients clinically indicated for an echocardiographic examination using an additional point of care ultrasound device . the images collected will be used to test and possibly validation an ai base aortic valve stenosis algorithm

this is a non-randomized, un-blinded single-arm study in patients scheduled for a standard echocardiographic examination. participants will be scanned by a sonographer (study exam) and 6 standard views will be obtained using both the ultrasound systems: plax, psax-av, ap4, ap2, ap3 and ap5 . the patient will undergo their scheduled echocardiographic examination either before or after the study examinations. the findings from the clinically indicated echocardiographic examination will be used as a gold standard for the presence/absence and severity of aortic stenosis. the first 45 patients, 15 with mild, 15 with moderate and 15 with severe as, will be used for testing and possible fine-tuning the autoas algorithm for each study device, and the remaining up to 155 patients for each study device will be used for clinical validation of the algorithm. because these first 45 patients will only be used for possible fine-tuning the autoas algorithm, they will be excluded from endpoint analysis.

Eligibility criteria:
inclusion criteria: * patients scheduled for an echocardiographic examination * patients ≥18 years old * patient with known or suspected valve disease based on medical history exclusion criteria: * patients with artificial aortic valves * unable to lie flat for study * patients experiencing a known or suspected acute cardiac event * patients unwilling or unable to give written informed consent
letrozole as a treatment of endometrial cancer

Conditions: Endometrial Carcinoma

Summary: some cases of endometrial cancer are dependent on estrogen for their growth. letrozole blocks estrogen production in the body. the purpose of this study is to determine if the investigators can predict which patients might benefit from letrozole treatment by studying the many different forms of the estrogen receptor molecule that exist within the cancer tissues. to participate in this study, the patients must be 40 years of age or older and have biopsy-proven endometrial carcinoma, either well differentiated or moderately differentiated forms. also, to be eligible to participate in this study, the patients need to be healthy enough to have a hysterectomy. if the patients are less than age 60, they will need a blood test (fsh) to confirm that they have gone into menopause.


Eligibility criteria:
inclusion criteria: * figo grade 1 or 2 endometrioid adenocarcinoma of the endometrium * post menopausal status must be demonstrated * signed informed consent exclusion criteria: * figo grade 3 endometrioid adenocarcinoma or non-endometrioid cancers of the endometrium * younger than 40 or postmenopausal status not established * pregnant or breastfeeding

Keywords: endometrial cancer endometrial carcinoma aromatase inhibitor letrozole femara
long-term use of pegaptanib in patients for subfoveal choroidal neovascularization secondary to age-related macular degeneration

Conditions: Macular Degeneration

Summary: the objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the lpd (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3) factors considered to affect the safety and/or efficacy of this drug.

all the patients whom an investigator prescribes the first macugen® should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.

Eligibility criteria:
inclusion criteria: * patients need to be administered macugen® in order to be enrolled in the surveillance. exclusion criteria: * patients not administered macugen®.

Keywords: subfoveal choroidal neovascularization secondary to age-related macular degeneration
infection prevention and control intervention to reduce hospital-acquired infections

Conditions: Hospital-acquired Infections

Summary: hospital-acquired infections (hais) are significant public health issues, especially in low- and middle-income countries (lmics). hand hygiene and low-level disinfection of equipment (llde) practices among healthcare workers (hcws) are essential to reduce hais. various effective infection prevention and control (ipc) interventions to reduce hai incidence have been developed. however, which interventions work effectively in lmics has not been identified. the investigators aim to develop, pilot, and assess the feasibility and acceptability of an ipc intervention in cambodia and the lao people's democratic republic (pdr).

this study consists of four phases guided by the medical research council (mrc) framework. three hospitals from each country will be selected. in phase 1, the investigators will conduct a gap analysis of ipc implementation and practices among hcws at each hospital through desk review, direct observation of hand hygiene and llde practices, in-depth interviews with hcws, and key informant interviews with stakeholders. in phase 2, the investigators will develop an ipc intervention based on results from phase 1 and interventions selected from the literature review of ipc interventions in lmics. in phase 3, the investigators will pilot the developed intervention in the same hospitals selected in phase 1. finally, in phase 4, the investigators will assess the feasibility and acceptability of the developed intervention among hcws and stakeholders at the selected hospitals. the investigators will employ the mrc framework to develop and evaluate an intervention to reduce hais in both countries. the investigators will also use a theoretical framework to explore factors that are barriers and enablers for hcws to improve hand hygiene compliance. with these approaches, the investigators will be able to develop a comprehensive intervention. findings from this study would shed light on promising ipc interventions to reduce hai incidence in cambodia and lao pdr. more importantly, the findings may be applied to other lmic settings.

Eligibility criteria:
inclusion criteria: * healthcare workers working in the selected wards and of chosen hospitals * aged 18 years or above * working in the selected wards of the chosen hospitals for at least six months * being able and agreeing to provide informed consent to participate in the study exclusion criteria: - interns and visiting healthcare workers

Keywords: infection control prevention hand hygiene healthcare workers low- and middle-income countries asia
impacts trial: investigation of the modulation of phospholipase in acute chest syndrome

Conditions: Sickle Cell Disease; Vaso-occlusive Crisis; Acute Chest Syndrome

Summary: the study will be conducted at 15-20 us centers in a randomized, placebo-controlled, double-blind fashion. enrollees will be hospitalized sickle cell disease (scd) patients at-risk for acute chest syndrome (acs) based on the presence of vaso-occlusive crisis (voc), fever (t ≥38.0°c) and serum spla2 concentration ≥50 ng/ml.

this is a double-blind randomized, parallel group, placebo-controlled dose escalation study (2 cohorts) in patients with sickle cell disease (scd) and vaso-occlusive crisis (voc) who are at-risk for development of acute chest syndrome (acs) based on the combination of voc, fever (t ≥38.0ºc), and a serum spla2 concentration ≥50 ng/ml. the first group of patients will be randomized 2:1 to receive low dose a-001 or placebo as a 48-hour continuous infusion. pharmacokinetic and clinical data from this group will undergo review by the independent data monitoring committee (idmc). if there is no significant toxicity associated with a-001, then an additional group of patients will be enrolled and randomized 2:1 to high dose a-001 versus placebo as a 48-hour continuous infusion.

Eligibility criteria:
patients are eligible for inclusion if they meet the following criteria: * sickle cell variant (hb ss, hb sc, sickle β°-thalassemia, sickle β+-thalassemia) * pain consistent with vaso-occlusive crisis * elevated serum spla2 level (measured on-site) * fever * age ≥5 years (through adult) patients must not meet any of the following exclusion criteria: * new lung infiltrate by chest radiography * pregnancy or breastfeeding * significant renal dysfunction * significant hepatic dysfunction * acute neurologic dysfunction * any medical condition for which transfusion may be needed imminently, and/or hemoglobin \<5 g/dl * red blood cell transfusion within 30 days of entry into the study
the effect of propofol on dexamethasone-induced perineal pruritus

Conditions: Pruritus

Summary: patients may appear serious perineal itching, after injection of dexamethasone sodium phosphate injection its incidence is about 25% \~ 100%, and the incidence of the discomfort in females was much higher than that of the maleto investigate the effect of propofol pretreatment on perineal pruritus induced by dexamethasone sodium phosphate injection and explore the possible machanisms.

40 patients scheduled for selective surgery,aged 18-65years,asa physical status i\~ii,bmi 18\~30kg/m2 were selected in this study.the patients were equally randomized into two groups: propofol (p) group and normal saline (n) group, 20 cases in each group. before anesthesia induction, m group received intravenous injection of 0.3mg/kg propofol , while n group received corresponding intravenous normal saline of the same volume. after 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg. the anesthesiologist assessed perineal irritation in both groups and recorded ramsay scores,the number of cases, visual analogue scale(vas) scores ,duration of itching and observed the occurrence of adverse reactions such as dizziness, hypotension and respiratory depression in the two groups.

Eligibility criteria:
inclusion criteria: * elective female surgery patients, ages 18 to 65 years old, asa ⅰ or ⅱ level, body mass index (bmi) of 18 \~ 30 kg/m2. exclusion criteria: * diabetes mellitus, paresthesia, allergy to narcotic drugs, routine preoperative use of narcotic analgesics, long-term use of hormones, drug and alcohol abuse, communication disorders in psychiatric disorders, pregnancy or lactation, and patients with severe systemic diseases and unwilling to undergo the trial.

Keywords: propofol; dexamethasone; pruritus